Idogen AB (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. Idogen’s intention is to revolutionize the treatment of several disorders in which the body’s immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.
Project and Communications Manager
Idogen AB Medicon Village Scheelevägen 2 SE 223 81 Lund Sweden
+46 723 868458
Idogen AB Medicon Village Scheelevägen 2 223 81 Lund
+46 709 180010